Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Innovation Pharmaceuticals Inc (EM) IPIX

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.


EXPM:IPIX - Post by User

Post by Brito1on Sep 15, 2020 2:31pm
180 Views
Post# 31561065

More great thoughts

More great thoughtsAnother great post, thanks to The poster Mo Thoughts on today's announcement: - Todays news is outstanding in that it will get Brilacidin additional attention with the scientific community and investment community. - Leo will move forward with a solo Brilacidin human trial initially. - The fact that the RBL ran the Remdesivir tests indicate that the government is interested in improving their current investment and a combo trial could take place very quickly. - This combo number further solidifies the odds of IPIX getting grant funding. - The current Administration has been looking for a cure for CV19. Once this 100% effectiveness number is communicated (any day) a UUUGE press conference proclamation would give IPIX immediate worldwide attention. - The rapid deployment of Brilacidin can take place without IPIX needing a partner in the U.S. An international BP distribution channel partnership may take place. - IMO any discussion of an IPIX buyout is very pre-mature. The quickest path to market for Brilacidin is to deploy the planned Phase 2 CV19 human trial with a rapid advancement to Emergency Use Authorization. This is the best path for treating the CV19 pandemic and is also the best path for IPIX investors. IPIX does not need a buyout or even a BP partnership for this to happen. Once Brilacidin is approved by the FDA for CV19 the value of the Brilacidin franchise vastly increases. Every Brilacidin instance approved including B-IBD UC and B-OM will greatly add to Brilacidins franchise value. - Today is one of 8-10 IPIX PRs that could take place in the next 2 months. Great things are happening at IPIX and the science will win. - Each announcement will put more pressure on the criminals that control IPIX SP. One of the upcoming IPIX PRs or a government press conference will gap IPIX SP to several dollars along with multiple trading days of record volume which will signal the criminals losing their grip. - How much is the Gold Standard Treatment for CV19 worth? See post #65303 Read More: https://investorshangout.com/post/view?id=5894356#ixzz6Y8UACsJx
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities